Isoquinolinone derivatives and their use as therapeutic agents

Details Isoquinolinone derivatives and their use as therapeutic agents Isoquinolinone derivatives and their use as therapeutic agents

2007-09-04

2007-09-04

Davis, Zinna N. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S141000

Reexamination Certificate

active

10738964

ABSTRACT:
Compounds of formula (I):wherein n, R1, R2, R3and R7are disclosed herein, are useful in treating disease-states associated with nuclear receptor activity. Pharmaceutical compositions comprising and methods of using said compounds are also disclosed herein.

REFERENCES:
patent: 3452027 (1969-06-01), Myles et al.
patent: 4198512 (1980-04-01), Kubo et al.
patent: 5260316 (1993-11-01), Van Duzer et al.
patent: 5334600 (1994-08-01), Van Duzer et al.
patent: 5350761 (1994-09-01), Van Duzer et al.
patent: 5607898 (1997-03-01), Nakamura et al.
patent: 5607967 (1997-03-01), Friedman et al.
patent: 5665733 (1997-09-01), Servin et al.
patent: 5747661 (1998-05-01), Evans et al.
patent: 5945380 (1999-08-01), Gallenkamp et al.
patent: 6184215 (2001-02-01), Elias et al.
patent: 6187814 (2001-02-01), Elias et al.
patent: 6316503 (2001-11-01), Li et al.
patent: 2003/0073614 (2003-04-01), Schulman et al.
patent: 424929 (1991-05-01), None
patent: 591937 (1996-04-01), None
patent: 526402 (1998-01-01), None
patent: 845460 (1998-06-01), None
patent: 999208 (2000-05-01), None
patent: WO97/43263 (1997-11-01), None
patent: WO98/00423 (1998-01-01), None
patent: WO98/28268 (1998-07-01), None
patent: WO99/32485 (1999-07-01), None
patent: WO 00/17334 (2000-03-01), None
patent: WO 00/37077 (2000-06-01), None
patent: WO 00/57915 (2000-10-01), None
patent: WO 00/66611 (2000-11-01), None
patent: WO 00/78972 (2000-12-01), None
patent: WO 01/15676 (2001-03-01), None
patent: WO 01/60818 (2001-08-01), None
patent: WO 01/77067 (2001-10-01), None
patent: WO 01/82917 (2001-11-01), None
patent: WO 02/11708 (2002-02-01), None
patent: WO 02/062764 (2002-08-01), None
patent: WO 03/076418 (2003-09-01), None
Connors et al, Can. J. Chem, vol. 74, pp. 221-226, 1994.
Aicart et al, Journal of Heterocyclic Chemistry, vol. 22, pp. 921-925, 1985.
Couture et al, Synthesis, vol. 7, pp. 576-578, Jul. 1986.
Couture et al, Journal of Organic Chemistry, vol. 56, No. 16, pp. 4977-4980, 1991.
GenBank Database, Accession No. BC012646, Jun. 29, 2004. Available from www.ncbi.nlm.nih.gov/entrez/.
GenBank Database, Accession No. NM—002957, Jun. 14, 2005. Available from www.ncbi.nlm.nih.gov/entrez/.
GenBank Database, Accession No. NM—005123, Jul. 19, 2005. Available from www.ncbi.nlm.nih.gov/entrez/.
GenBank Database, Accession No. NM—009473, Jul. 4, 2005. Available from www.ncbi.nlm.nih.gov/entrez/.
GenBank Database, Accession No. NM—031626, Apr. 20, 2005. Available from www.ncbi.nlm.nih.gov/entrez/.
GenBank Database, Accession No. NM—031627, Apr. 20, 2005. Available from www.ncbi.nlm.nih.gov/entrez/.
GenBank Database, Accession No. U07132, Jan. 29, 1995. Available from www.ncbi.nlm.nih.gov/entrez/.
GenBank Database, Accession No. U10375, Jul. 22, 1994. Available from www.ncbi.nlm.nih.gov/entrez/.
GenBank Database, Accession No. U18374, Jun. 21, 1995. Available from www.ncbi.nlm.nih.gov/entrez/.
GenBank Database, Accession No. U22662, Jan. 27, 1996. Available from www.ncbi.nlm.nih.gov/entrez/.
GenBank Database, Accession No. X57638, Apr. 18, 2005. Available from www.ncbi.nlm.nih.gov/entrez/.
GenBank Database, Accession No. XM—042579, Feb. 6, 2002. Available from www.ncbi.nlm.nih.gov/entrez/.
GenBank Database, Accession No. XM—053680, May 8, 2002. Available from www.ncbi.nlm.nih.gov/entrez/.
Akakura and Yamamoto, “Methylalumoxane as a Highly Lewis Acidic Reagent for Organic Synthesis,”Synlett(3): 277-278, Mar. 1997.
Baumgarth, M. et al., “(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+Antiporter Inhibitors,”Journal of Medicinal Chemistry 40(13): 2017-2034, Jun. 20, 1997.
Beugelmans and Bois-Choussy, “A Common and General Access to Berberine and Benzo [c] Phenathridine Alkaloids,”Tetrahedron 48(38): 8285-8294, 1992.
Cheon, S.H. et al., “Sturucture-Activity Relationship Studies of Isoquinolinone Type Anticancer Agent,”Arch. Pharm. Res. 24(4): 276-280, 2001.
Chiasson, J-L. et al., “The efficacy of Acarbose in the Treatment of Patients with Non-Insulin-dependent Diabetes Mellitus,”Annals of Internal Medicine 121(12): 928-935, Dec. 15, 1994.
Comins and Brown, “Ortho Metalation by α-Amino Alkoxides,”The Journal of Organic Chemistry 49(6): 1078-1083, Mar. 23, 1984.
Coniff and Krol, “Acarbose: A Review of US Clinical Experience,”Clinical Theapeutics 19(1): 16-26, Jan.-Feb. 1997.
Coniff, R.F. etal., “Multicenter, Placebo-Controlled Trial Comparing Acarbose (BAY g 5421) With Pacebo, Tolbutamide, and Tolbutamide-Plus-Acarbose in Non-Insulin-Dependent Diabetes Mellitus,”The American Journal of Medicine 98: 443-451, May 1995.
Couture, A. et al., “A New Synthetic Route to 2-Methyl-3-(Aryl or Alkyl)-1-Oxo-1,2-Dihydroisoquinolines via an Intramolecular Wittig Reacation,”Tetrahedron 48(19): 3857-3866, 1992.
Couture, A. et al., “Fluoride ion-induced cyclization ofo-[bis(trimethysilyl)methyl]-N-acylbenzamide derivatives. New efficient synthesis of 2,3,-differentially substituted 1(2H)-isoquinolones,”Journal of the Chemical Society, Perkin Transactions 1: 469-476, 1997.
Couture, A. et al., “Intramolecular Peterson olefination ofortho-trimethylsilylmethyl-N-acyl-N-alkylbenzamides. A new route to 2-alkyl-1(2H)isoquinolones,”Journal of Organometallic Chemistry 440(1-2): 7-13, Nov. 17, 1992.
Davis, S.E. et al., “The Preparation of Substituted 1(2H)-Isoquinolinones from Dilithiated 2-Methyl-N-Arylbenzamides, 2-Methyl-N-(Arylmethyl)-Benzamide, or 2-Methylbenzoic Acid, 2,2-Dimethylhydrazide,”Synethetic Communications 27(17): 2961-2969, 1997.
De Wet, J.R. et al., “Firefly Luciferase Gene: Structure and Expression Mammalian Cells,”Molecular and Cellular Biology 7(2): 725-737, Feb. 1987.
Gaillard, O. et al., “Apolipoprotein E intrathecal synthesis is decreased in multiple sclerosis patients,”Annals of Clinical Biochemistry 33(Part 2): 148-150, Mar. 1996.
Haffner, S.M., “Management of Dyslipidemia in Adults With Diabetes,”Diabetes Care 21(1): 160-178, Jan. 1998.
Haimova, M.A. et al., “One-Pot Synthesis of 5,6-Dihydro-8H-dibenzo[a,g]quinolizine-8-ones and Related Isoquinolines; A New Synthesis of Xylopinine,”Synthesis(10): 845-847, 1980.
Koller, M.U. et al., “The Preparaion of Substituted 1(2H)-Isoquinolones From Polylithiated 2-(2-Methylphenyl)Hydrazainecarboxylic Acid Esters,”Synthetic Communications 26(9): 1763-1774, 1996.
Kwiterovich, P.O., “State-of-the-Art Update and Review: Clinical Trials of Lipid-Lowering Agents,”The American Journal of Cardiology 82(12A): 3U-17U, Dec. 17, 1998.
Luckow and Schütz, “CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements,”Nucleic Acids Research 15(13): 5490, 1987.
Mahler and Adler, “Clinical Review 102. Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment,”The Journal of Clinical Endocrinology&Metabolism 84(4): 1165-1171, 1999.
Mali, R.S. et al., “A Convenient Synthesis ofN-Methyl-1(2H)-isoquinolones,”Synthesis(4): 329-330, Apr. 1982.
Ohta, S. et al., “Synthesis of 3-Substituted Isocoumarins and Related Natural Products,”Chemical&Pharmaceutical Bulletin 41(6): 1188-1190, 1993.
Oitzl, M.S. et al., “Severe learning deficits in apolipoprotein E-knockout mice in a water maze task,”Brain Research 752:189-196, 1997.
Peet, D.J. et al., “Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXRα,”Cell 93(5): 693-704, May 29, 1998.
Poirier, J., “Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease,”Trends in Neurosciences 17(12): 525-530, Dec. 1994.
Roselaar and Daugherty, “Apolipoprotein E-deficient mice have impaired innate immune responses toListeria monocytogenesin vivo,”Journal of Lipid Research 39:1740-1743, 1998.
Sinal, C.J. et al., &

Affiliated with

Also associated with

Rating

Isoquinolinone derivatives and their use as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Isoquinolinone derivatives and their use as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoquinolinone derivatives and their use as therapeutic agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3746504